P53及其相关蛋白对X射线照射肝癌细胞周期的调节

X射线照射人肝癌细胞HepG2,照射后细胞存活随照射剂量增大明显下降。流式细胞术分析,不同剂量组照射后24h均发生G2期阻滞。照射后不同时间组的细胞周期分布也有不同,照射后12h,有显著的S期延迟。Western Blot显示照射后24hP53,MDM2,P21蛋白表达上升,并有时间效应:P53在照射后24h之内始终维持较高表达,MDM2和P21分别在照射后6和12h的表达最高。X射线照射通过影响P53及其相关蛋白的表达影响细胞周期。

p53基因转导联合重离子辐射引起小鼠黑色素瘤细胞生长抑制及其机制的探讨

为了将放射治疗与基因治疗有机结合起来以寻求有效治疗恶性黑色素瘤的方法，采用了AdCMV-p53（AdCMV-GFP）转染B16细胞联合重离子（或X－射线）辐照的方法，观察辐射对基因转移效率的影响、外源性P53蛋白对重离子辐照诱导肿瘤细胞生长抑制和辐射增敏作用，以及外源性P53蛋白对重离子辐照诱导肿瘤细胞内蛋白表达的变化，现将本工作结果总结如下： 1.重离子照射可增加腺病毒载体介导p53基因转导效率，而且先转染后辐照法比先辐照后转染法能更显著的地增加基因转导效率。这样在最大限度提高基因转导效率的基础之上，同时又可以减少病毒使用量及辐照剂量。 2.p53基因转导联合重离子辐照能明显抑制细胞生长，诱导细胞凋亡，促进G0/G1期细胞阻滞。说明外源性野生型p53基因导入联合辐照可增加黑色素瘤细胞系B16的辐射敏感性。 3.重离子照射比X-射线照射能更明显增加腺病毒载体介导p53基因转导效率和G0/G1期细胞所占比例，可能是由于两种射线能量沉积的方式不同造成的。 4.重离子辐照联合p53基因转导诱导B16细胞中细胞信号通路发生变化，使得P53和P21表达明显增多，同时MDM2表达随时间而减少。推测导入的p53基因联合重离子辐照改变细胞内信号通路，从而诱导细胞凋亡和细胞周期阻滞

碳离子束联合p53腺病毒重组体转染对肿瘤细胞生物学效应研究

肿瘤是严重威胁人类生命健康的常见病、多发病，不仅病因复杂、发生发展异常迅速，而且到目前为止，发病机理不完全清楚，尚无适应范围广和有特异疗效的治疗方法。因此，肿瘤治疗方法的探索依然是医学、生物学及其相关学科研究的热点。肿瘤的重离子治疗和基因治疗是近年来发展起来的新的肿瘤治疗方法。但它们同样或多或少存在一些不足。在肿瘤治疗方法的探索中，将两种或两种以上理化特性或生物学作用原理不尽相同的现有治疗方法有机结合，充分利用各自优势，取长补短，使治疗效果叠加，对肿瘤发挥协同或相加抑制作用。本研究将重离子辐射与p53腺病毒重组体(AdCMV-p53)转染有机结合，探讨了重离子辐射联合p53基因转导对肿瘤细胞的生物学作用及其可能机理。在低剂量γ辐射联合AdCMV-p53/GFP转染HT-29和PC-3细胞研究基础上，我们用不同剂量的AdCMV-p53/GFP转染经0.5 Gy、1.0 Gy、2.0 Gy 12C6+束/γ射线预辐射处理的人非小细胞肺癌(H1299细胞系，nullp53)，人肝癌细胞(HepG2细胞系，wtp53)和人宫颈癌细胞(Hela细胞系，wtp53，wtp53低水平表达)。用流式细胞分析法检测肿瘤细胞绿色荧光蛋白(GFP)、p53蛋白表达水平和细胞周期。DAPI染色后用荧光显微镜检测细胞凋亡。用RT-PCR检测外源性p53转录。用Western Blot检测外源性p53、MDM2和p21蛋白表达。用克隆形成法测定肿瘤细胞存活。通过与γ辐射联合腺病毒重组体转染组比较，观察了12C6+ 辐射联合腺病毒重组体转染对肿瘤细胞外源性p53蛋白表达、细胞周期阻滞、细胞凋亡和细胞增殖的影响。结果显示，12C6+ 辐射对AdCMV-GFP转染H1299、HepG2和Hela细胞的诱导作用明显强于γ辐射(p<0.05)。与γ辐射诱导AdCMV-GFP转染组相比，0.5 Gy 12C6+束辐射联合20 MOI AdCMV-p53转染组H1299细胞GFP阳性率增加约50% (其GFP阳性率提高到约90%)。0.5 Gy、1.0 Gy 12C6+辐射联合40 MOI AdCMV-p53转染组HepG2细胞GFP阳性率增加约44%(其阳性率分别达56.6%和76.4%)。0.5 Gy、1.0 Gy 12C6+ 束辐射联合40 MOI AdCMV-p53转染组Hela细胞GFP阳性率分别增加37.8%和50%(其阳性率分别达43.4%和59.8%)。12C6+ 辐射对AdCMV-p53转染H1299、HepG2和Hela细胞外源性p53蛋白表达的增强作用明显强于γ辐射(p<0.05)。12C6+ 辐射联合AdCMV-p53转染组各种细胞p53阳性率明显高于其它处理组同种细胞p53阳性率(p<0.05)。转染后第5天，γ辐射联合AdCMV-p53转染组3种细胞p53阳性率均降至对照水平。转染后第13天，12C6+ 辐射联合AdCMV-p53转染组3种细胞p53阳性率仍高达6－44%。12C6+ 辐射联合AdCMV-p53转染H1299细胞G0/G1、G2/M期细胞所占比例明显高于其它处理组G0/G1、G2/M期细胞所占比例(p<0.05)。与γ辐射联合AdCMV-p53转染组相比，12C6+ 辐射联合AdCMV-p53转染组G0/G1期细胞增加6－36%，G2/M期细胞增加了13－86%。12C6+ 辐射联合AdCMV-p53转染HepG2细胞G0/G1期细胞所占比例明显高于其它处理组G0/G1期细胞所占比例(p<0.05)；转染后第5天，1.0、2.0 Gy 12C6+ 辐射联合AdCMV-p53转染组G2/M期细胞所占比例明显高于γ辐射联合AdCMV-p53转染组G2/M期细胞所占比例(p<0.05)。各12C6+束辐射联合AdCMV-p53转染Hela细胞G0/G1和G2/M期细胞所占比例均明显高于单纯12C6+ 辐射组和γ射线辐射联合AdCMV-p53转染组G0/G1和G2/M期细胞所占比例(p<0.05)。各12C6+ 辐射联合AdCMV-p53转染H1299、HepG2和Hela细胞凋亡率明显高于等剂量12C6+ 单纯辐射和等剂量γ辐射联合AdCMV-p53转染组细胞凋亡率(p<0.05)。与等剂量单纯12C6+辐射和等剂量γ辐射联合AdCMV-p53转染组相比，12C6+ 辐射联合AdCMV-p53转染H1299细胞凋亡率分别增加8.0－66.0%和9.3－63.5%；12C6+束辐射联合AdCMV-p53转染HepG2细胞凋亡率分别增加0.8－32.7%和4.5－27.1%； 12C6+束辐射联合AdCMV-p53转染Hela细胞凋亡率分别增加4.8－30.7%和3.1－22.7%。低剂量12C6+ 辐射联合AdCMV-p53转染细胞存活率明显低于其它处理组同种细胞存活率(p<0.05)。结果提示，低剂量碳离子辐射对腺病毒重组体转染肿瘤细胞和靶细胞内外源p53蛋白表达的促进作用明显强于低剂量γ辐射。碳离子辐射联合AdCMV-p53转染通过促进外源性p53转导、靶细胞外源性p53蛋白表达、细胞周期阻滞和细胞凋亡等增强对肿瘤细胞的抑制。碳离子辐射联合AdCMV-p53转染对肿瘤细胞生物学作用与肿瘤细胞内在p53基因状态有关。总之，我们的研究表明，低剂量碳离子辐射联合AdCMV-p53转染，可通过促进腺病毒重组体对肿瘤细胞的转染、增强靶细胞外源性p53蛋白稳定表达及其由此而诱发的细胞周期阻滞与细胞凋亡等有效抑制肿瘤细胞。在临床上，碳离子辐射联合AdCMV-p53转染有望在提高肿瘤治疗效果的基础上，进一步降低碳离子辐射与AdCMV-p53转染的各自临床用量，减少碳离子辐射的毒副作用，降低AdCMV-p53转染的潜在生物危险性

beta-arrestin-1 competitively inhibits insulin-induced ubiquitination and degradation of insulin receptor substrate 1.

beta-arrestin-1 is an adaptor protein that mediates agonist-dependent internalization and desensitization of G-protein-coupled receptors (GPCRs) and also participates in the process of heterologous desensitization between receptor tyrosine kinases and GPCR signaling. In the present study, we determined whether beta-arrestin-1 is involved in insulin-induced insulin receptor substrate 1 (IRS-1) degradation. Overexpression of wild-type (WT) beta-arrestin-1 attenuated insulin-induced degradation of IRS-1, leading to increased insulin signaling downstream of IRS-1. When endogenous beta-arrestin-1 was knocked down by transfection of beta-arrestin-1 small interfering RNA, insulin-induced IRS-1 degradation was enhanced. Insulin stimulated the association of IRS-1 and Mdm2, an E3 ubiquitin ligase, and this association was inhibited to overexpression of WT beta-arrestin-1, which led by decreased ubiquitin content of IRS-1, suggesting that both beta-arrestin-1 and IRS-1 competitively bind to Mdm2. In summary, we have found the following: (i) beta-arrestin-1 can alter insulin signaling by inhibiting insulin-induced proteasomal degradation of IRS-1; (ii) beta-arrestin-1 decreases the rate of ubiquitination of IRS-1 by competitively binding to endogenous Mdm2, an E3 ligase that can ubiquitinate IRS-1; (iii) dephosphorylation of S412 on beta-arrestin and the amino terminus of beta-arrestin-1 are required for this effect of beta-arrestin on IRS-1 degradation; and (iv) inhibition of beta-arrestin-1 leads to enhanced IRS-1 degradation and accentuated cellular insulin resistance.

Ubiquitylation of p53 by the APC/C inhibitor Trim39.

Tripartite motif 39 (Trim39) is a RING domain-containing E3 ubiquitin ligase able to inhibit the anaphase-promoting complex (APC/C) directly. Through analysis of Trim39 function in p53-positive and p53-negative cells, we have found, surprisingly, that p53-positive cells lacking Trim39 could not traverse the G1/S transition. This effect did not result from disinhibition of the APC/C. Moreover, although Trim39 loss inhibited etoposide-induced apoptosis in p53-negative cells, apoptosis was enhanced by Trim39 knockdown in p53-positive cells. Furthermore, we show here that the Trim39 can directly bind and ubiquitylate p53 in vitro and in vivo, leading to p53 degradation. Depletion of Trim39 significantly increased p53 protein levels and cell growth retardation in multiple cell lines. We found that the relative importance of Trim39 and the well-characterized p53-directed E3 ligase, murine double minute 2 (MDM2), varied between cell types. In cells that were relatively insensitive to the MDM2 inhibitor, nutlin-3a, apoptosis could be markedly enhanced by siRNA directed against Trim39. As such, Trim39 may serve as a potential therapeutic target in tumors with WT p53 when MDM2 inhibition is insufficient to elevate p53 levels and apoptosis.

Apoptosis and cell-cycle regulatory proteins in colorectal carcinoma: relationship to tumour stage and patient survival

The quantitative assessment of apoptotic index (AI) and mitotic index (MI) and the immunoreactivity of p53, bcl-2, p21, and mdm2 were examined in tumour and adjacent normal tissue samples from 30 patients with colonic and 22 with rectal adenocarcinoma. Individual features and combined profiles were correlated with clinicopathological parameters and patient survival data to assess their prognostic value. Increased AI was significantly associated with increased bcl-2 expression (p

Clinical and immunohistochemical assessment of vulval intraepithelial neoplasia following photodynamic therapy using a novel bioadhesive patch-type system loaded with 5-aminolevulinic acid

Background: The work in this study appraised photodynamic treatment (PDT) as a treatment method for vulval intraepithelial neoplasia (VIN) using a novel bioadhesive patch to deliver aminolevulinic acid. An analysis of changes in expression of apoptotic and cell cycle proteins (p53, p21, Mdm2, Blc-2, Bax, Ki-67) in response to PDT was evaluated. Methods: PDT was performed using non-laser light, either as a one or two-cycle treatment, with clinical and pathological assessment following after 6 weeks. Twenty-three patients with 25 VIN lesions underwent 49 cycles of PDT Patches were designed to conform to uneven vulval skin and contained 38 mg cm(-2) aminolevulinic acid. Assessment was carried out at 6 weeks post-treatment. Patient-based treatment assessment, along with clinical and pathological changes, were monitored. Immunohistochemical staining was used to elucidate a possible biomolecular basis for induced cellular changes. Results: Most patients (52%) reported a symptomatic response, with normal pathology restored in 38% of lesions. The patch was easy to apply and remove, causing minimal discomfort. Fluorescence inspection confirmed protoporphyrin accumulation. Pain during implementation of PDT was problematic, necessitating some form of local analgesia. Changes in expression of cell cycle and apoptotic-related proteins suggested involvement of apoptotic pathways. Down regulation of p21 and inverse changes in Bcl-2 and Bax were key findings. Conclusion: Treatment of VIN lesions using a novel bioadhesive patch induced changes in cell cycle and apoptotic proteins in response to PDT with possible utilisation of apoptotic pathways. The efficacy of PDT in treating VIN could be improved by a better understanding of these apoptotic mechanisms, the influence of factors, such as HPV status, and of the need for effective pain management.

Ribosomal 18S RNA processing by the IGF-I-responsive WDR3 protein is integrated with p53 function in cancer cell proliferation.

Insulin-like growth factor-I (IGF-I) signaling is strongly associated with cell growth and regulates the rate of synthesis of the rRNA precursor, the first and the key stage of ribosome biogenesis. In a screen for mediators of IGF-I signaling in cancer, we recently identified several ribosome-related proteins, including NEP1 (nucleolar essential protein 1) and WDR3 (WD repeat 3), whose homologues in yeast function in ribosome processing. The WDR3 gene and its locus on chromosome 1p12-13 have previously been linked with malignancy. Here we show that IGF-I induces expression of WDR3 in transformed cells. WDR3 depletion causes defects in ribosome biogenesis by affecting 18 S rRNA processing and also causes a transient down-regulation of precursor rRNA levels with moderate repression of RNA polymerase I activity. Suppression of WDR3 in cells expressing functional p53 reduced proliferation and arrested cells in the G1 phase of the cell cycle. This was associated with activation of p53 and sequestration of MDM2 by ribosomal protein L11. Cells lacking functional p53 did not undergo cell cycle arrest upon suppression of WDR3. Overall, the data indicate that WDR3 has an essential function in 40 S ribosomal subunit synthesis and in ribosomal stress signaling to p53-mediated regulation of cell cycle progression in cancer cells.

MicroRNA-34c inversely couples the biological functions of the runt-related transcription factor RUNX2 and the tumor suppressor p53 in osteosarcoma

Osteosarcoma (OS) is a primary bone tumor that is most prevalent during adolescence. RUNX2, which stimulates differentiation and suppresses proliferation of osteoblasts, is deregulated in OS. Here, we define pathological roles of RUNX2 in the etiology of OS and mechanisms by which RUNX2 expression is stimulated. RUNX2 is often highly expressed in human OS biopsies and cell lines. Small interference RNA (siRNA)-mediated depletion of RUNX2 inhibits growth of U2OS OS cells. RUNX2 levels are inversely linked to loss of p53 (which predisposes to OS) in distinct OS cell lines and osteoblasts. RUNX2 protein levels decrease upon stabilization of p53 with the MDM2 inhibitor Nutlin-3. Elevated RUNX2 protein expression is post-transcriptionally regulated and directly linked to diminished expression of several validated RUNX2 targeting microRNAs (miRNAs) in human OS cells compared to mesenchymal progenitor cells. The p53-dependent miR-34c is the most significantly down-regulated RUNX2 targeting miRNA in OS. Exogenous supplementation of miR-34c markedly decreases RUNX2 protein levels, while 3UTR reporter assays establish RUNX2 as a direct target of miR-34c in OS cells. Importantly, Nutlin-3 mediated stabilization of p53 increases expression of miR-34c and decreases RUNX2. Thus, a novel RUNX2-p53-miR34 network controls cell growth of osseous cells and is compromised in OS.

AKT in Stromal Fibroblasts Controls Invasion of Epithelial Cells

The tumour microenvironment has an important role in cancer progression and recent reports have proposed that stromal AKT is activated and regulates tumourigenesis and invasion. We have shown, by immuno-fluorescent analysis of oro-pharyngeal cancer biopsies, an increase in AKT activity in tumour associated stromal fibroblasts compared to normal stromal fibroblasts. Using organotypic raft co-cultures, we show that activation of stromal AKT can induce the invasion of keratinocytes expressing the HPV type 16 E6 and E7 proteins, in a Keratinocyte Growth Factor (KGF) dependent manner. By depleting stromal fibroblasts of each of the three AKT isoforms independently, or through using isoform specific inhibitors, we determined that stromal AKT2 is an essential regulator of invasion and show in oro-pharyngeal cancers that AKT2 specific phosphorylation events are also identified in stromal fibroblasts. Depletion of stromal AKT2 inhibits epithelial invasion through activating a protective pathway counteracting KGF mediated invasions. AKT2 depletion in fibroblasts stimulates the cleavage and release of IL1B from stromal fibroblasts resulting in down-regulation of the KGF receptor (fibroblast growth factor receptor 2B (FGFR2B)) expression in the epithelium. We also show that high IL1B is associated with increased overall survival in a cohort of patients with oro-pharyngeal cancers. Our findings demonstrate the importance of stromal derived growth factors and cytokines in regulating the process of tumour cell invasion.

STAT3 regulated ARF expression suppresses prostate cancer metastasis

Prostate cancer (PCa) is the most prevalent cancer in men. Hyperactive STAT3 is thought to be oncogenic in PCa. However, targeting of the IL-6/STAT3 axis in PCa patients has failed to provide therapeutic benefit. Here we show that genetic inactivation of Stat3 or IL-6 signalling in a Pten-deficient PCa mouse model accelerates cancer progression leading to metastasis. Mechanistically, we identify p19(ARF) as a direct Stat3 target. Loss of Stat3 signalling disrupts the ARF-Mdm2-p53 tumour suppressor axis bypassing senescence. Strikingly, we also identify STAT3 and CDKN2A mutations in primary human PCa. STAT3 and CDKN2A deletions co-occurred with high frequency in PCa metastases. In accordance, loss of STAT3 and p14(ARF) expression in patient tumours correlates with increased risk of disease recurrence and metastatic PCa. Thus, STAT3 and ARF may be prognostic markers to stratify high from low risk PCa patients. Our findings challenge the current discussion on therapeutic benefit or risk of IL-6/STAT3 inhibition.

Characterization of TRIB2 following PI3K inhibition

Dissertação de mestrado, Oncobiologia,(Mecanismos Moleculares do Cancro), Departamento de Ciências Biomédicas e Medicina, Universidade do Algarve, 2015

Development of a new cellular model for the visualization and study of GFAP oligomerization in living cells

Tese de mestrado, Neurociências, Faculdade de Medicina, Universidade de Lisboa, 2016

Methylation profile of TP53 regulatory pathway and mtDNA alterations in breast cancer patients lacking TP53 mutations.

The present study investigated promoter hypermethylation of TP53 regulatory pathways providing a potential link between epigenetic changes and mitochondrial DNA (mtDNA) alterations in breast cancer patients lacking a TP53 mutation. The possibility of using the cancer-specific alterations in serum samples as a blood-based test was also explored. Triple-matched samples (cancerous tissues, matched adjacent normal tissues and serum samples) from breast cancer patients were screened for TP53 mutations, and the promoter methylation profile of P14(ARF), MDM2, TP53 and PTEN genes was analyzed as well as mtDNA alterations, including D-loop mutations and mtDNA content. In the studied cohort, no mutation was found in TP53 (DNA-binding domain). Comparison of P14(ARF) and PTEN methylation patterns showed significant hypermethylation levels in tumor tissues (P < 0.05 and <0.01, respectively) whereas the TP53 tumor suppressor gene was not hypermethylated (P < 0.511). The proportion of PTEN methylation was significantly higher in serum than in the normal tissues and it has a significant correlation to tumor tissues (P < 0.05). mtDNA analysis revealed 36.36% somatic and 90.91% germline mutations in the D-loop region and also significant mtDNA depletion in tumor tissues (P < 0.01). In addition, the mtDNA content in matched serum was significantly lower than in the normal tissues (P < 0.05). These data can provide an insight into the management of a therapeutic approach based on the reversal of epigenetic silencing of the crucial genes involved in regulatory pathways of the tumor suppressor TP53. Additionally, release of significant aberrant methylated PTEN in matched serum samples might represent a promising biomarker for breast cancer.

Growth factor activation of ErbB2/ErbB3 signaling pathways regulate the activity of Estrogen Receptors (ER)

La signalisation par l’estrogène a longtemps été considérée comme jouant un rôle critique dans le développement et la progression des cancers hormono-dépendants tel que le cancer du sein. Deux tiers des cancers du sein expriment le récepteur des estrogènes (ER) qui constitue un élément indiscutable dans cette pathologie. L’acquisition d’une résistance endocrinienne est cependant un obstacle majeur au traitement de cette forme de cancer. L’émergence de cancers hormono-indépendants peut est produite par l’activation de ER en absence d’estrogène, l’hypersensibilité du récepteur aux faibles concentrations plasmique d’estrogène ainsi que l’activation de ER par des modulateurs sélectifs. L’activité du ER est fortement influencée par l’environnement cellulaire tel que l’activation de voie de signalisation des facteurs de croissances, la disponibilité de protéines co-régulatrices et des séquences promotrices ciblées. Présentement, les études ont principalement considérées le rôle de ERα, cependant avec la découverte de ERβ, notre compréhension de la diversité des mécanismes potentiels impliquant des réponses ER-dépendantes s’est améliorée. L’activation des voies des kinases par les facteurs de croissance entraîne le développement d’un phénotype tumoral résistant aux traitements actuels. Nos connaissances des voies impliquées dans l’activation de ER sont restreintes. ERα est considéré comme le sous-type dominant et corrèle avec la plupart des facteurs de pronostic dans le cancer du sein. Le rôle de ERβ reste imprécis. Les résultats présentés dans cette thèse ont pour objectif de mieux comprendre l’implication de ERβ dans la prolifération cellulaire par l’étude du comportement de ERβ et ERα suite à l’activation des voies de signalisation par les facteurs de croissance. Nous démontrons que l’activation des récepteurs de surfaces de la famille ErbB, spécifiquement ErbB2/ErbB3, inhibe l’activité transcriptionnelle de ERβ, malgré la présence du coactivateur CBP, tout en activant ERα. De plus, l’inhibition de ERβ est attribuée à un résidu sérine (Ser-255) situé dans la région charnière, absente dans ERα. Des études supplémentaires de ErbB2/ErbB3 ont révélé qu’ils activent la voie PI3K/Akt ciblant à son tour la Ser-255. En effet, cette phosphorylation de ERβ par PI3K/Akt induit une augmentation de l’ubiquitination du récepteur qui promeut sa dégradation par le système ubiquitine-protéasome. Cette dégradation est spécifique pour ERβ. De façon intéressante, la dégradation par le protéasome requiert la présence du coactivateur CBP normalement requis pour l’activité transcriptionnelle des récepteurs nucléaires. Malgré le fait que l’activation de la voie PI3K/Akt corrèle avec une diminution de l’expression des gènes sous le contrôle de ERβ, on observe une augmentation de la prolifération des cellules cancéreuses. L’inhibition de la dégradation de ERβ réduit cette prolifération excessive causée par le traitement avec Hrgβ1, un ligand de ErbB3. Un nombre croissant d’évidences indique que les voies de signalisations des facteurs de croissance peuvent sélectivement réguler l’activité transcriptionnelle de sous-types de ER. De plus, le ratio ERα/ERβ dans les cancers du sein devient un outil de diagnostique populaire afin de déterminer la sévérité d’une tumeur. En conclusion, la caractérisation moléculaire du couplage entre la signalisation des facteurs de croissance et la fonction des ERs permettra le développement de nouveaux traitements afin de limiter l’apparition de cellules tumorales résistantes aux thérapies endocriniennes actuelles.